{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.4"},{"groupId":"OG001","value":"88.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"Percentage of patients who had minimal residual disease (MRD) \\< 0.01% among those with isolated BM or combined BM relapse \\>= 36 months and had successful MRD determinations at End Block 3.","groups":[{"description":"Standard VCR dosing (1.5 mg/m\\^2, max 2mg)","id":"OG000","title":"Regimen A"},{"description":"Intensive VCR dosing (2 mg/m\\^2, max 2.5 mg)","id":"OG001","title":"Regimen B"}],"paramType":"NUMBER","populationDescription":"This analysis is limited to all eligible patients with isolated BM or combined BM relapse \\>= 36 months and had successful MRD determinations at End Block 3.","reportingStatus":"POSTED","timeFrame":"End of Block 3 (105 days) of Induction therapy","title":"Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3","type":"SECONDARY","unitOfMeasure":"percentage of participants"}